CHRS Historical PE Ratio Notes

— Coherus BioSciences (CHRS) is a biopharmaceutical company focused on developing and commercializing biosimilar medicines, as well as innovative therapies in oncology and immunology. Its main products include biosimilars of established biologic drugs, such as UDENYCA® (pegfilgrastim-cbqv) and CIMERLI® (ranibizumab-eqrn), which aim to offer lower-cost alternatives to expensive branded biologics. The company’s strategy depends heavily on navigating complex regulatory pathways, competing in markets with powerful incumbents, and achieving cost efficiencies. Because of these challenges, CHRS has seen periods of fluctuating earnings, investment in R&D, and changing revenue streams as new products launch or patents expire. These dynamics contribute to historical volatility in its price-to-earnings (PE) ratio, as investors evaluate prospects for sustained profitability amid evolving competition and industry cycles. When you review CHRS’s historical PE ratio charts, keep in mind that periods of negative or very high PE ratios often reflect early-stage investment phases, product launches, or earnings volatility rather than stable, mature profitability. Thus, the company’s fundamentals and its lifecycle stage have a significant impact on the historical valuations assigned to its stock.

On this page we presented the CHRS Historical PE Ratio information for Coherus BioSciences' stock. The average CHRS historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 48.5. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CHRS historical PE based on this TTM earnings result method is 13.5. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CHRS historical PE result, against the recent PE: when this page was posted on 8/19/2026, the most recent closing price for CHRS had been 1.33, and the most recent quarterly earnings result, annualized, was 0.04. Meanwhile, the most recent TTM earnings summed to 0.35. From these numbers, we calculate the recent CHRS PE on 8/19/2026 based on annualized quarterly EPS was 33.2. Based on CHRS's history, that recent PE is low relative to the historical average, with the recent PE 31.5% lower than the historical average PE across our data set for Coherus BioSciences. Looking at the recent CHRS PE on 8/19/2026 based on TTM EPS, we calculate the ratio at 3.8. Based on CHRS's history, that recent PE is low relative to the historical average, with the recent PE 71.9% lower than the average PE across our Coherus BioSciences data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on CHRS or any other given stock, valuation analysis for CHRS can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Coherus BioSciences PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CHRS. Thanks for visiting, and the next time you need to research CHRS Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.